A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with 5-Azacytidine in Patients with Recurrent, Resectable Osteosarcoma

Administered By

Awarded By

Contributors

Start/End

  • February 26, 2021 - June 30, 2022